Blog | Multibagger Shares

June 6, 2026

Infographic-like hero showing Joel Greenblatt's framework: a gold-outlined 2x2 matrix on a dark blue background with descriptive text panels and a large white title below reading 'Where the Institutions Cannot Follow'.

The Secret Hiding Places: Joel Greenblatt’s 1997 Special-Situations Framework and Why the Long-Term Equity Investor Should Hunt Where the Forced Seller, Not the Forecast, Sets the Price

Joel Greenblatt's 1997 framework finds mispricing not in better forecasts but in forced sellers — corporate events that hand orphaned securities to holders mandated to dump them. An educational look at the mechanism, the evidence, and the discipline it asks of the long-term investor.

May 24, 2026

Hero title: "Wonderful Business at a Fair Price" with subtitle about Buffett and Indian compounds, on a dark blue background.

Wonderful Business at a Fair Price: The See’s Candies Pivot That Reshaped Buffett’s Mind in 1972 – and Why It Justifies Owning Quality Indian Compounders Today

In January 1972 Buffett wrote a $25 million cheque for See's Candies - the single most consequential trade of his career. Here is why Indian value investors must abandon cigar-butt thinking and pay for quality.

May 23, 2026

Headline: Marathon’s Capital Cycle Theory with a green accent bar and subtitle against a dark blue gradient background, centered donut chart labeled FY25 Reinvested at the bottom.

Marathon’s Capital Cycle Theory: The Supply-Side Framework That Spots India’s Next Multibagger Industries Before the Headlines Do

Marathon Asset Management's Capital Cycle Theory tells Indian value investors to count plants, not consumers — the supply-side framework that predicts industry returns better than any demand forecast.

May 22, 2026

Hero section introducing Chris Mayer’s 100-Bagger Framework with four quadrants labeled Trader, COMPOUNDER, Drift, and Speculator beneath the title.

Chris Mayer’s 100-Baggers Framework: The Seven Empirical Attributes Behind Every Hundred-Bagger Stock

Christopher Mayer's 365-stock empirical study extracted seven attributes that predicted 100x compounders. Titan Biotech FY25 illustrates five of the seven on a small-cap Indian balance sheet.